NCT05726175 2023-02-13Disitamab Vedotin(RC48) Combined With Penpulimab(AK105) for Neoadjuvant Treatment of HER2-low Breast CancerWest China HospitalPhase 2 Unknown20 enrolled
NCT05244993 2022-07-12AK105 Plus Anlotinib Hydrochloride Combined With Albumin Paclitaxel as a First-line Therapy in Patients With Advanced Triple-negative Breast CancerLiaoning Cancer Hospital & InstitutePhase 2 Unknown42 enrolled